* If you want to update the article please login/register
About half of GvHD patients were steroid-resistant with a two-year overall survival rate lower than 20%. Notably, pioneering researchers have emphasized the clinical or therapeutic benefits of human umbilical cord-derived mesenchymal stem/stromal cells on GvHD, owing to their unique hematopoietic-supporting and immunomodulatory properties. In addition, the GvHD administration's oversight policy and medical ethics, as well as the concomitant risks and challenges, have been discussed.
Source link: https://europepmc.org/article/MED/35619293
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions